ABSTRACT
Chloroquine (CQ) and hydroxychloroquine (HCQ) have shown mixed effects in clinical studies of COVID-19 disease. We aimed to comprehensively assess how CQ and HCQ affected COVID-19 patient outcomes. Method(s): We combed through a wide range of archives, preprints, and grey literature up through the date of November 17, 2022. Using a random-effects model, we combined only the mortality estimates that had their effects accounted for. We summed up how CQ or HCQ affected viral clearance, ICU admission, and the need for mechanical ventilation. All of the databases MEDLINE, CINAHL, EMBASE, Web of Science, Google scholar, LILACS, and Scopus were searched electronically from their inceptions in the 1950s without regard to publication date or language availability up until November 2022. In total, 6 articles were used for the evaluation. Patients who are subjected to be treated with Chloroquine or Hydroxychloroquine against Corona viral infections Six randomised clinical trials (RCTs) met the criteria, therefore these findings can be considered. There is some evidence to show that HCQ is effective in lowering short-term mortality in COVID-19 hospitalised patients or the risk of hospitalisation in COVID-19 outpatients. Finally, these results should be taken into account in the follow-up care of patients who will be admitted for COVID-19 treatmen and may help in their clinical management. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.